Amgen’s ‘Imdelltra’ breaks ‘1-year survival barrier in SCLC – “i didn’t know it would be this good”
Amgen's Imdelltra (tarlatamab) showed significant results in a Phase 3 trial for small cell lung cancer (SCLC), extending median overall survival to 13.6 months, a 5.3-month improvement over chemotherapy. The trial, involving 509 patients, demonstrated a 40% reduction in death risk. Imdelltra is already approved in Korea for extensive-stage SCLC and has expanded indications.
How this was made
The 30-second read
Why it matters
The trial data could accelerate global regulatory submissions and expand market share in the SCLC space.
Market read
First‑time disclosure of pivotal trial results for a major biotech, likely to move Amgen stock and influence the oncology sector.
What to watch
Potential competition from emerging immunotherapies and the drug's safety profile could temper upside.
Background
Amgen's Imdelltra (tarlatamab) is a bispecific T‑cell engager targeting DLL3 and CD3, recently approved in Korea and now showing Phase 3 efficacy.
Ticker impact
Amgen announced Phase 3 DeLLphi-304 trial results showing median overall survival of 13.6 months for Imdelltra, a 40% reduction in death risk.
likely upside as the market prices in the survival benefit and potential label expansion
First disclosure of pivotal Phase 3 data for a bispecific antibody in a high‑mortality cancer; large‑cap biotech with significant market exposure.
Market effects
strengthens the oncology/biotech sector outlook, may boost peers developing bispecific antibodies.
positive for US biotech equities; Asian markets may see modest gains due to trial participation.
adds to global cancer‑therapy pipeline confidence, could influence investor sentiment worldwide.
Counterpoint
Skeptics may question long‑term durability of survival benefit and regulatory hurdles.
Key entities
- CompanyAmgen
US biotech firm developing Imdelltra.
- DrugImdelltra (tarlatamab)
Bispecific antibody for extensive‑stage small cell lung cancer.
